Compare Revvity Inc (RVTY) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Revvity Inc trades at $153 (market cap $17.30B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Revvity Inc is far larger — about 3.5× Travere Therapeutics Inc. Common Stock's market cap, and Revvity Inc pays a 0.18% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 13 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| RVTY | TVTX | |
|---|---|---|
Market Cap | $17.30B | $4.88B |
Volume | 1,387,588 | 1,668,577 |
Sector | Health | Health |
52-Week High | $157.36 | $67.52 |
52-Week Low | $82.26 | $26.79 |
Typical Hold Time | 13 Days | 0 Days |
Enterprise Value | $19.62B | $5.01B |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $155.08, down 0.34% on the day but near its 52-week high of $158.28. The stock shows strong technical momentum with bullish moving averages and has consistently beaten earnings estimates in recent quarters. Recent developments include the launch of a new diabetes detection kit in Europe and the acquisition of Human Cell Design to expand metabolic disease research capabilities. The company maintains solid profitability with 54.98% gross margins and positive cash flow trends.
RVTY presents growth potential through diagnostic expansion and AI-driven demand, though premium valuation metrics (P/E 74.56) require careful consideration. Near-term catalysts include Q3 earnings on November 3, 2026, while risks involve China market pressures and margin compression. Analyst consensus leans bullish with 52% buy ratings and a $132.13 price target, suggesting potential downside from current levels despite positive momentum.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
